Skip to content
OpenCapital
Get started

Agios Pharmaceuticals AGIO Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number

Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number at other companies

Precigen logo
PrecigenPGEN
——
Ligand Pharmaceuticals logo
Ligand PharmaceuticalsLGND
——

Other financials

Income statement

See full
Revenue$20.7M+138%
Gross profit$19.4M+154%
Operating income-$110.0M-3.2%
Net income-$99.1M-11.0%
EPS (diluted)-$1.69-9.0%

Balance sheet

See full
Cash & equivalents$113.6M+43.9%
Total debt$35.7M-32.5%
Total equity$1.1B-24.4%
Total assets$1.2B-23.8%

Cash flow

See full
Operating cash flow-$118.9M-6.7%
CapEx$769.0K+0.4%
Free cash flow-$119.7M-6.6%

Valuation

See full
Market cap$2.16B+18.1%

Profitability

See full
Gross margin90%+2.5pp
Operating margin-720%-204pp
Net margin-639.8%—
FCF margin-582.5%-185pp

Returns & leverage

See full
Return on equity-32.8%—
Debt / equity0×0.0×
Current ratio14.2×-4.3×

Where this comes from

Reported directly by Agios Pharmaceuticals in its filing.

Tagged under the XBRL concept us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber.

The official record: Agios Pharmaceuticals’s 10-Q, filed April 29, 2026, on SEC EDGAR. View the filing →

Ask your AI about Agios Pharmaceuticals's share based compensation arrangement by share based payment award options exercisable number.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Agios Pharmaceuticals's share based compensation arrangement by share based payment award options exercisable number?
Agios Pharmaceuticals (AGIO) reported share based compensation arrangement by share based payment award options exercisable number of $4.52M in Q1 2026.
How has Agios Pharmaceuticals's share based compensation arrangement by share based payment award options exercisable number changed year-over-year?
Agios Pharmaceuticals's share based compensation arrangement by share based payment award options exercisable number increased by 12.3% year-over-year, from $4.02M to $4.52M.